There is a great deal of misinformation about silver solutions. While there are several kinds (ionic, colloidal, nano technology, protein silver), the safety of silver is extraordinary, despite the fear of turning blue (argyria) which has been promulgated over the years.

The truth is that virtually no one has ever turned blue because of a deposition of silver particles in the skin. In the documented case where this has happened, the person drank huge and irrational amounts of silver daily for decades. In the recent well-publicized case of a politician who was supposed to have turned blue from drinking silver, it turned out to be a hoax perpetrated by his political opponents in the campaign for office he was participating in.

The smaller the particle size, the more effective the silver is at disrupting the biological function of disease causing bacteria, mycoplasma and viruses. The smaller the particle size, the more efficiently the body can get rid of the silver.

The silver we recommend, ASAP silver sol solution is exceedingly small in size, has never been shown to provide any medical or health problems and has been used for people from infancy to people in their 90s.

Here are the facts as I see them, after extensive experience using silver for infections of all types:
1. Silver in nano sized particles does not cause argyria because the particles are small enough to pass easily out of the urine, rather than being deposited in tissues. No case of argyria has ever been reported with nano particle silver
2. As you said, the amounts you would have to consume border on the insane.
3. Nano silver is effective, without any known side effects, against every pathogen it has been tested against
4. Through its applications in Africa, we know that pregnant women, tiny babies, fragile elderly, people with diabetes, cancer, auto immune disease, etc., do not develop side effects when they take silver as directed.
5. No ulcers have ever been reported with nano silver
6. The silver we recommend has been shown NOT to kill beneficial bacteria, thus protecting the integrity of the gut and the immune system.

ASAP silver sol solution has been tested against more than 650 pathogenic organisms and has been effective in vitro (in the lab) against every one. It has also been tested against the normal bacteria (which we refer to collectively as “pro biotics”) and found, rather amazingly, to spare these beneficial bacteria.

I personally never travel without ASAP silver sol solution. I have used it for common ailments like a cold and uncommon ones like malaria. It can be taken via sub lingual administration directly under the tongue to speed absorption and prevent it from reaching the GI tract or it can be mixed in a small amount of water and taken by mouth. It has no flavor or taste so even babies can take it without distress.

We have concluded a special arrangement with Nutronix.com to allow us to offer you this silver sol solution. Please do yourself a favor and lay in a good supply of this outstanding health aid.

Click here, http://www.Nutronix.com/naturalsolutions, to get your supply. Click on the “Products” tab, then go to the left hand column and click on “Silver Solutions”.

It is not clear how long the FDA will allow this exceptional product to remain on the market. I suggest you stockpile it for pandemics, general disease use and immune system boosting.

Yours in health and freedom,
Dr. Rima
Medical Director
Natural Solutions Foundation
www.HealthFreedomUSA.org
www.GlobalHealthFreedom.org
www.NaturalSolutionsFoundation.org
www.Organics4U.org
www.NaturalSolutionsMarketPlace.org
www.NaturalSolutionsMedia.tv

Effect of Prophylactic Treatment with ASAP-AGX-32 and ASAP Solutions on an Avian Influenza A (H5N1) Virus Infection in Mice

Gordon Pedersen,American Biotech Labs

Sidwell, Robert W., The Institute for Antiviral Research of Utah State University Animal, Dairy and Veterinary Sciences Dept

Alan Moloff, D.O., M.P.H., Colonel, MC, U.S. Army (RET)

Robert W. Saum Ph.D., IDHA, Medical Science and Technology, American Biotech Labs

Introduction

Avian Influenza (H5N1, or Bird Flu) can be a fatal disease in humans and a serious threat to become a pandemic event. Since there is no pharmaceutical remedy for the Bird Flu it is essential that preventive treatments be tested and developed in order to enhance survivor rates in the human population.

Since 1973, Silver has been shown to have topical activity against 22 bacterial species (643 isolates) including gram positive and gram negative bacteria1. As an antimicrobial agent, Silver has been shown to be beneficial in the treatment and prevention of burn infections, post surgical wound infections, and gynecological infections2, 3. In addition, Silver has been shown to be active against black mold4, Anthrax5, Bubonic plague6, Malaria7, and numerous viruses such as Hepatitis 8.

Recently it was reported that the American Biotech Labs product, Silver Sol, demonstrated additive and synergistic effects when combined in individual trials with 19 different antibiotics9. The Silver
from ABL was shown to improve the effectiveness of the antibiotics even against
antibiotic resistant infections 9.

The Merck Index identifies the following medicinal uses of silver: Antiseptic particularly for mucous membranes and infectious sinusitis10. The Merck Manual and Centers for Disease Control, recommend that Silver nitrate drops should be placed in each infant eye as soon as possible or at least in the first half hour of life to prevent gonorrheal ophthalmia 11.

The safe use of Silver as an orally consumed preventive agent has been demonstrated and supported by reports from the EPA and the United States Department of Health and Human Services in a 76 week long study12,13. Dogs that inhaled Silver showed activity in the lung in one hour with 90% of the silver carried to the liver by the blood within 6 hours14.

Due to the increased risk from methicillin resistant bacteria, black mold, plasmodium and especially bird flu, the need for orally consumed, safe, daily prophylactic prevention exists. In this study, Silver Sol from American Biotech Labs demonstrates safe beneficial and preventive activity against H5N1 Bird Flu, when taken orally in mice.

The American Biotech Labs product, ASAP- AGX-32, as well as their product designated ASAP, to be virucidal against the avian influenza A/Vietnam/1203/2004 (H5N1) x A/Ann Arbor/6/60 hybrid virus, with an up to 2 log10 virus titer reduction occurring after a 6 h incubation of the product and the virus
(USU report dated March 28, 2006). In that same report, similar incubation with the avian influenza A/Duck/MN/1525/81 (H5N1) virus reduced the virus titer by approximately one-half log10 in the same
time period. This material is reportedly very well tolerated in human subjects when ingested orally, Dr Gordon Pedersen of American Biotech Labs designed a study with the Centers for Antiviral Research to
evaluate the potential for ASAP-AGX-32 and ASAP, to inhibit an avian influenza A (H5N1) virus infection of mice when administered orally to the animals beginning 1 week prior to virus exposure. This report describes the results of this experiment.

Materials and Methods

Animals: Female specific pathogen-free 18- 21 g BALB/c mice were obtained from Charles River Laboratories (Wilmington, MA). They were quarantined 5 days prior to use. They were housed in polycarbonate cages with stainless steel tops and provided tap water and mouse chow ad libitum.

Virus: Influenza A/Duck/MN/1525/81 (H5N1) virus was originally provided by Dr Robert Webster of the St. Jude Hospital (Memphis, TN). The virus was adapted to mice by passage twice through weanling animals and a large pool prepared in MDCK cells for use in this study. The virus was titrated in young
adult mice prior to use in the present experiment.

Compounds: ASAP and ASAP-AGX-32 were provided by Dr Pedersen. They were in blue bottles, so all studies run with each were performed using the materials in injection bottles covered with aluminum foil to avoid light exposure. All were stored at room temperature until used. It is understood that the ASAP solution contained a colloidal silver at a concentration of 10 ppm, and the ASAP-AGX-32 contained the same colloidal silver at a concentration of 32 ppm. Ribavirin, included as a known positive
control, was provided by ICN Pharmaceuticals, Inc. (Costa Mesa, CA); it was dissolved in sterile saline and stored at 4o C until used.

Arterial Oxygen Saturation (SaO2) Determinations: SaO2 was determined using the Ohmeda Biox 3800 pulse oximeter (Ohmeda, Louisville, OH). The ear probe attachment was used, the probe paced on the thigh of the animal. Readings were made after a 30 sec stabilization time on each animal. Use of an earlier Ohmeda Model (3740) for measuring effects of influenza virus on SaO2 in mice has been previously described by Dr.s Sidwell and Pedersen15.

Lung Score Determinations: Each mouse lung removed and placed in a petri dish which, using a permanent black marker, had been divided into sections which were pre- numbered from 1 through 3 or, for placebo controls, 1 through 5. Each lung was assigned a score ranging from 0 (normal appearing lung) to 4 (maximal plum coloration in 100% of lung). These scores were assigned blindly, with the individual doing the scoring not being aware of what group was being examined. An arithmetic mean was determined for each group.

Lung Virus Titer Determinations: Each mouse lung was homogenized and varying dilutions assayed in triplicate for infectious virus in MDCK cells as described previously16. Each lung homogenate was
centrifuged at 2000 g for 5 min and the supernatents used in these assays.

Experimental Design: Groups of 19 mice were treated by oral gavage (p.o.) with either ASAP-AGX-32 or ASAP twice daily (every 12 h) for 7 days, then infected intranasally (i.n.) with an LD70 dose of
influenza virus, then treated an additional 10 days. A similar group of mice were treated p.o. with ribavirin at a dosage of 75 mg/kg/day twice daily for 5 days beginning 4h pre-virus exposure. The infection was achieved by anesthetizing the mice with an intraperitoneal injection of Ketamine at a dosage of 100 mg/kg and instilling 90 µl of suspended virus in minimum essential medium on the nares of the animals. As controls, 35 mice were treated with water using the identical schedule as used for the
ASAP materials and infected as above. Ten infected, test substance-treated mice and 20 water-treated controls were observed daily for deaths for 21 days after virus exposure, and SaO2 levels ascertained on days 3-11, which were the times when this parameter usually declines. From the remaining infected, treated animals, 3 test substance-treated and 5 water-treated control mice were killed on days 1, 3 and 6, and their lungs removed, assigned a consolidation score, weighed, and assayed for virus titer.

As toxicity controls, 3 uninfected mice were treated in parallel with each test material and observed for signs of adverse effects for 21 days. The weights of these mice as well as 5 normal controls were determined prior to initial treatment and again 18 h after final treatment to determine if the treatments
affected host weight gain. Three normal controls were also sacrificed on days 3 and 6 to provide background lung data.

Statistical Analysis

Increases in total survivors were evaluated by chi square analysis with Yates’ correction. Increases in
mean day to death, differences in mean SaO2 values, mean lung weight, and mean virus titers were analyzed by t-test. Only animals dying up to day 21 were considered for mean day to death calculations. The Wilcoxon ranked sum analysis was used for mean lung score comparisons. Each
statistical test was run using Excel software on a MacIntosh computer.

Results and Discussion

The results of this experiment are summarized in Table 1 and in Figures 1-4. As seen in Table 1, the virus challenge in this experiment was lethal to 14 of the 20 placebo-treated mice, with the mean day to
death being 8.4 days. Such a pattern of death is considered ideal for evaluation of potential antiviral agents. This optimal condition was verified by the observation that Ribavirin was fully protective to the
mice, preventing any deaths from occurring (Table 1), significantly lessening SaO2 declines (Figure 1), inhibiting lung score development (Figure 2), lung weight increase (Figure 3), and lung virus titer
increases (Figure 4).

Treatment with ASAP-AGX-32 appeared to not affect the numbers of animals dying of influenza, although a half-day delay in mean day to death was seen (Table 1). SaO2 declines in this group of treated mice were almost at the same rate as those in the placebo controls, although it was interesting
that on the first day this parameter was assayed, a highly significant (P<0.001) difference was seen (Figure 1). SaO2 declines are a manifestation of declining lung function, suggesting that the lung consolidation in the lungs did not progress as rapidly as seen in the placebo controls. The treatment appeared to moderately lessen lung consolidation as seen by lower lung scores on each time evaluated, the day 6 mean lung score being significantly (P<0.05) less than the placebo treated controls (Figure 2). Lung weights, another indication of fluid developing in the lungs to cause pneumonia in the animal, were also less at each time point than seen in the placebos (Figure 3). The mean lung virus titers in the mice treated with ASAP-AGX-32 were lower than the placebo controls on days 3 and 6 of the infection (Figure 4). Treatment with ASAP, which we understand is a less-concentrated version of ASAP-AGV- 32, also provided some intriguing results. Especially of interest was the observation that 60% of the infected mice treated with this compound survived compared to the 30% in the placebo-treated controls. Although not statistically significant because of the number which survived in the latter controls, this effect is strongly suggestive a disease-inhibitory effect may have occurred. At two time points during the SaO2 assays, days 3 and 6, the declines normally seen were significantly lessened (P<0.01), and there was a general lessening of decline throughout the times of assay (Figure 1). Modest inhibition in lung scores were seen in this treated group as well, especially on day 6 (Figure 2); the lung weight data did not correlate too well with the lung scores, however (Figure 3). Again, slight inhibition of lung virus titers were seen in the ASAP- treated, infected mice (Figure 4). Both the ASAP formulations were well tolerated by the toxicity control mice as seen by no deaths occurring in them and host weight increases observed during time of therapy. Ribavirin, while not lethal to the mice, did result in a 0.4 g host weight loss (Table 1); this was an expected effect for the latter material, since the maximum tolerated dose is approximately 100 mg/kg/day. It is difficult to attribute the effects seen in this experiment wholly to viral inactivation, since both test materials were administered orally to animals infected by direct nasal inhalation, although the treatments began one week before virus exposure, so it is possible that a portion of the Silver Sol may have been able to be in the vicinity of the virus-exposed lung tissue. It is also possible that this material is exerting a mild immunomodulatory effect in the animals, which would provide modest protection against the infection. If such a mechanism is indeed associated with the potential activity seen, then a different treatment schedule, perhaps limiting the number of treatments to one per day or once every other day, may enhance any immune modulatory effects, since it is recognized that too-frequent dosing may overtax the immune system. The greater protection seen by the lower- dosed ASAP material could be explained by immunomodulation, since the greatest immunologic effect is not necessarily at the highest dose used. Another mechanism whereby the ASAP materials may have inhibited the influenza virus infection in these studies may simply be one of coating the virion with Silver Sol to prevent attachment and penetration. Again, the material would need to be in the vicinity of the exposed lung tissues at the time infection was initiated. The Silver material could also play a role in limiting apoptosis of the epithelial lining of the lung induced during acute lung inflammation. Apoptosis plays a causative role in acute lung injury in part due to epithelial cell loss. Further studies would have to be conducted to more fully delineate the actions of this material. It is acknowledged that the effects seen in the present study, while of considerable interest, would need to be repeated to confirm that the observations were not due to mere chance. Consideration of combined use of oral administration of the ASAP materials and intranasal instillation at near the time of virus exposure would determine whether the effects seen were indeed associated with virucidal effects of these materials. Summary

Mice infected with avian influenza A/Duck/MN/1525/81 (H5N1) virus were treated with the Silver Sol-containing formulations ASAP-AGX-32 and ASAP provided by American Biotech Labs. Oral gavage treatment began 7 days prior to virus exposure and continued twice daily for a total of 17 days. Treatments with both formulations provided a suggested inhibitory and preventive effect on this virus infection as seen by either less animals dying in the treated groups than in the placebo-treated
controls, delay in mean day to death, lessened SaO2 decline, modest inhibition of lung consolidation, and/or lessened virus titers in the lungs. Ribavirin was included as a positive control drug, used orally at a dose of 75 mg/kg/day twice daily for 5 days beginning 4 h pre-virus exposure, and this treatment was markedly inhibitory to the infection as expected.

References

1. Carr, H., Wlodowski, T., 1973. Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York. Antimicrobial Agents and Chemotherapy. 10:585-587.

2. Fox, C. J. Jr., 1968. Silver sulfadiazine, a new topical therapy for Pseudomonas burns. Arch. Surg. 96:184-188.

3. Fox, C. J., 1969. Control of Pseudomonas infection in burns by Silver Sulfadiazine. Surg.Gynecol. Obstet. 128:1021-1026.

4. U.S. House International Relations Committee, 2005. Written testimony on Black Mold.

5. Illinois Institute of Technology. 2001. Anthrax.

6. Robinson, R., 2003. Bactericidal activity of ASAP Silver Solution on Yersinia Pestis, the etiological agent of plague. Department of Microbiology, Brigham Young University.

7. U.S. House Relations Committee. 2005. Written testimony on Malaria.

8. Hafkine, A., 2003. ASAP antiviral activity in Hepatitis B; DNA Polymerase Inhibition, Reverse Transcriptase Inhibition. Hafkine Institute for Training, Research and Testing.

9. DeSousa, A., Mehta, D., Leavitt, R. W., 2006. Bactericidal activity of combinations of silver-water dispersion with 19 antibiotics against seven microbial strains. Current Science. 91:7- 11.

10. Merck Index, 2006. Silver 1:645.

11. Merck Index, 2006. Silver 1:2082.

12. EPA Research and Development, 1988. Drinking water criteria document for Silver. Office of Health and Environmental Assessment.

13. U.S. Department of Health and Human Services, Public Health Service and Agency for Toxic Substances and Disease Registry, 1990. Toxicological profile on Silver.

14. Phalen, R.F. and Morrow P.E., 1973. Experimental Inhalation of Metallic Silver, Health Physics 24: 509-518.

15. Sidwell, R.W., Huffman, J. H., Gilbert, J., Moscon, B. Pederson, G., Burger, R. and Warren, R.W. 1992. Utilization of pulse oximetry for the study of the inhibitory effects of antiviral agents on influenza
virus in mice. Antimicro Agents Chemother 36:473-6.

16. Sidwell, R.W., Huffman, J. H., Call, E.W., Alaghamandan, H., Cook, P.D, and Robins, R.K. 1985. Effect of Selenazofurin on influenza A and B virus infections in mice. Antiviral Res. 6:343-353.

Another theoretical “impossibility” becomes real by experiment. Water burning? Yes, it can!

Materials Research Innovations, March 2008, Vol 12, 3-5.

Table 1. Expt. ABLA-1. Effect of Oral Gavage Prophylactic Treatment with ASAP-AGX-32 and ASAP on an Influenza A (H5N1) Virus Infection in Mice.

Animals: Female 18-21 g BALB/c mice Virus: Influenza A/Duck/MN/1525/81 (H5N1) Drug diluent: Company diluent Treatment schedule: bid x 17 beg -7 days (Ribavirin: bid x 5 beg -4 h) Treatment route: p.o. Experiment. duration: 28 days Tax Controls Infected, Treated Mice Tax Controls Dosage
Surv/Total Mean Host Weight Change (g) Surv/Total Mean Day to Death ± SD Mean Day 11
SaO2 (% =± SD) ASAP- AGX- 32 32ppm 3/3 1.8 2/10 8.9 ± 1.4 75.4 ± 1.0
ASAP 10ppm 3/3 1.4 6/10 7.3 ± 1.0 76.7 ± 2.1 Ribavirin 75 mg/kg /day 3/3 -0.4 10/10*** >21.0 ± 0.0*** 86.6 ± 2.5** * H2O — — — 6/20 8.4 ± 1.8 76.0 ± 1.9 Norma l Contro ls — 5/5 2.3 — — 88.8 ± 3.0

Difference between initial weight and weight 18 h after final treatment.
Difference between initial weight and weight 18 h after final treatment.

*P<0.05; **P<0.01; ***P<0.001 compared to H2O -treated controls.